This trial is studying a gene therapy called Reqorsa given with the drug pembrolizumab to see if it can help to treat patients with previously treated non-small cell lung cancer.
3 Primary · 0 Secondary · Reporting Duration: Approximately 8 months
Active Control
Experimental Treatment
156 Total Participants · 4 Treatment Groups
Primary Treatment: pembrolizumab · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Texas | 100.0% |
18 - 65 | 100.0% |
Millennium Oncology | 100.0% |
Met criteria | 100.0% |